drugset

drugset / Trial / NCT00322517

Study Of The Efficacy And Safety Of SU-014813 In Patients With Metastatic Breast Cancer

NCT00322517 ↗

Phase 2 Completed 90 enrolled Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the antitumor efficacy and the safety of SU-014813 at a dose of 100 mg orally once daily in patients with Metastatic Breast Cancer

Timeline

Start: 2006-04
Primary completion: 2008-06
Completion: 2009-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SU014813	Small molecule	100 mg	Oral

Indications